Drug intelligence / Profile preview

MOG196-NPs

Development stage
Preclinical
Lead developer
Long Island University
Modality
Peptides, Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

MOG196-NPs is an investigational nanoparticle-based immunotherapy consisting of biodegradable poly(lactic-co-glycolic) acid (PLGA) nanoparticles encapsulating MOG196, a myelin oligodendrocyte glycoprotein peptide epitope, along with a dendritic cell (DC) activator and an MHC-E enhancer. Developed by TangGene and Long Island University, MOG196-NPs are designed to target and activate dendritic cells in vivo, promoting the presentation of the MOG196 peptide by nonclassical MHC class Ib molecules (HLA-E in humans and Qa-1 in mice). This presentation selectively stimulates and expands myelin-specific, MHC-E-restricted regulatory CD8 T cells (CD8 Tregs), which in turn suppress pathogenic autoreactive CD4 T cells. MOG196-NPs is being developed as a potential preventive and curative treatment for multiple sclerosis.

Other names
MOG196 nanoparticlesMOG-196 nanoparticlesMOG 196 nanoparticlesMOG196-NPMOG-196-NPMOG 196-NP
02

Targets

HLA-E (Human leukocyte antigen-e)MOG (Myelin oligodendrocyte glycoprotein)

Beyond the preview

Go deeper on MOG196-NPs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MOG196-NPs.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call